Letybo (Botulinum Toxin Type A)

Botulinum toxin type A acts at the neuromuscular junction by cleaving the SNAP‑25 protein, a key component of the vesicle‑fusion machinery required for acetylcholine release. By disabling SNAP‑25, the toxin blocks the exocytosis of acetylcholine from presynaptic nerve terminals, preventing the muscle‑activating signal. This results in a reversible, localized paralysis of the targeted muscle, lasting several months until new nerve terminals are formed.

The dose of Letybo is individualized and must be determined by a qualified healthcare professional. Dosing depends on the specific indication, the size and strength of the muscle being treated, and patient‑specific factors such as prior response and overall health. The prescriber calculates the appropriate units to inject and selects the injection sites, ensuring safe and effective treatment.

Safety data for Letybo in pregnancy and lactation are limited. It is classified as a precautionary product, and use is generally reserved for situations where the potential therapeutic benefit outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider before treatment.

To place an order, visit the product page for Letybo on the GNH India website (gnhindia.com) and submit an enquiry specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including cold‑chain logistics if needed—and assists with any required import documentation.

Letybo is a botulinum toxin type A formulation comparable in mechanism to other licensed products such as Botox® and Dysport®. While all share the same target—SNAP‑25 cleavage—their unit potencies, formulation excipients, and approved indications may differ slightly. Clinicians choose between products based on clinical experience, regulatory approvals in their region, dosing conventions, and patient‑specific response patterns.

Letybo must be stored refrigerated at temperatures between 2 °C and 8 °C. The vials should be kept in their original packaging to protect from light and must not be frozen or shaken, as this can reduce potency. Prior to administration, the product is typically reconstituted with sterile saline under aseptic conditions, and any unused portion should be discarded according to local regulations.

Letybo is given by intramuscular injection performed by a trained healthcare professional. The appropriate dose is drawn into a sterile syringe and injected directly into the targeted muscle or muscle group using a fine‑gauge needle. Injection sites and techniques vary according to the indication—for example, cervical muscles for dystonia or specific head muscles for migraine prophylaxis. Proper aseptic technique and accurate dosing are essential for optimal outcomes.

The most serious adverse events involve the spread of toxin beyond the intended injection site, which can lead to dysphagia, respiratory muscle weakness, generalized muscle weakness, or vision disturbances such as ptosis. Rarely, an allergic reaction ranging from rash to anaphylaxis may occur. Patients should be monitored closely after injection, and any signs of systemic weakness or breathing difficulty require immediate medical attention.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any of its excipients. It should also be avoided in patients with active infections at the proposed injection site, and used with caution in those with neuromuscular disorders such as myasthenia gravis, Lambert‑Eaton syndrome, or amyotrophic lateral sclerosis. Pregnant or breastfeeding women should only receive it after a thorough risk‑benefit assessment by their physician.